IPM Take
The sharp point is that brain health is no longer being framed as a specialist neurology issue alone. The European Parliament briefing turns it into a resilience question for ageing societies, labour markets, families and health systems. For IPM, this matters because personalised neurology will not scale through biomarkers and therapies alone. It needs earlier detection, coordinated care, caregiver support, research infrastructure and policies that treat neurological disease as a system burden before crisis points appear.
Executive Summary
A February 2026 European Parliament briefing, Strengthening Brain Health: Policy Recommendations to Tackle the Rising Burden of Neurological Diseases, calls for a coordinated European health plan dedicated to neurological health. The briefing states that brain health is shaped by genetic, lifestyle, environmental and social determinants, and that neurological diseases are among Europe’s most urgent and rapidly expanding health, social and economic challenges. It estimates the economic burden of selected neurological disorders in Europe at EUR 368 billion per year in 2019, with more than half attributed to informal care. It also notes that dementia cases in the EU27 are expected to grow from 9.1 million in 2025 to 14.3 million by 2050.
Why it matters
- Policymakers: Need to decide whether brain health becomes a coordinated EU agenda, rather than a fragmented set of disease-specific initiatives.
- Public authorities: Should prepare for rising pressure on diagnosis, long-term care, caregiver support and health-system capacity as populations age.
- Patients / advocates: Can use the briefing to push for earlier diagnosis, better access to specialist care and stronger support for families and informal caregivers.
Until now, neurological conditions were often treated as separate clinical problems: dementia, Parkinson’s disease, ALS, stroke, epilepsy or other neurological disorders. The policy response has been fragmented across research, care, disability support, ageing and social services.
What changes here is the system language. The European Parliament briefing links prevention, early diagnosis, research, innovation, effective therapies, care and social support in one policy frame. That makes brain health closer to cancer or cardiovascular health as a strategic public-health agenda, not only a specialist-care issue.
There is no single patient eligibility criterion because the document is policy-focused. The affected populations include people at risk of neurological decline, patients with neurodegenerative conditions, families providing informal care and health systems facing rising long-term care demand.
The implication is direct: Europe’s next brain-health agenda should not stop at innovation. It needs measurable readiness for diagnosis, referral, treatment, care coordination and caregiver support. If Europe wants personalised neurology to become real, it must first build the system conditions that allow patients to be identified, assessed and supported before avoidable decline and care breakdown occur.
